MedTrace Logo

When to Start Anti-HIV Drugs in Patients With Opportunistic Infections

NCT00055120 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 283

Last updated 2014-10-15

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of starting anti-HIV drugs in HIV infected patients who are being treated for opportunistic infections (OIs). This study will follow two patient groups: those who received anti-HIV drugs soon after being diagnosed with an OI and patients with OIs who deferred beginning anti-HIV drugs until after recovering from the OI.

Conditions

  • HIV Infections
  • AIDS-Related Opportunistic Infections

Interventions

DRUG

Emtricitabine/tenofovir disoproxil fumarate

DRUG

Lopinavir/ritonavir

DRUG

Stavudine

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    lead NIH

Principal Investigators

  • Andrew R. Zolopa, MD · Division of Infectious Diseases, Stanford University

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Primary Completion
2006-09-30
Completion
2007-08-31

Countries

  • United States
  • Puerto Rico
  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00055120 on ClinicalTrials.gov